File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Visual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors

TitleVisual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors
Authors
KeywordsAnastrozole
Exemestane
Letrozole
Macular hole
Retinal detachment
Issue Date2009
PublisherCancer Information Group, LP.
Citation
Clinical Breast Cancer, 2009, v. 9 n. 3, p. 184-186 How to Cite?
AbstractRetinal structure and function is maintained in part by the trophic effects of aromatase, a cytochrome P450 convertase responsible for local tissue estrogen synthesis from androgen precursors. Herein, we report deterioration of visual acuity in 2 Chinese patients with breast cancer and preexisting myopia who had recently commenced adjuvant hormonal therapy using the aromatase inhibitor exemestane. Given the neuroprotective functions of estrogen and aromatase, we caution that this timing might not be coincidental. Prompt ophthalmoscopic evaluation is thus recommended for any patient who is prescribed treatment with an aromatase inhibitor and subsequently develops visual symptoms.
Persistent Identifierhttp://hdl.handle.net/10722/78000
ISSN
2015 Impact Factor: 3.082
2015 SCImago Journal Rankings: 1.030
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorEpstein, RJen_HK
dc.date.accessioned2010-09-06T07:38:04Z-
dc.date.available2010-09-06T07:38:04Z-
dc.date.issued2009en_HK
dc.identifier.citationClinical Breast Cancer, 2009, v. 9 n. 3, p. 184-186en_HK
dc.identifier.issn1526-8209en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78000-
dc.description.abstractRetinal structure and function is maintained in part by the trophic effects of aromatase, a cytochrome P450 convertase responsible for local tissue estrogen synthesis from androgen precursors. Herein, we report deterioration of visual acuity in 2 Chinese patients with breast cancer and preexisting myopia who had recently commenced adjuvant hormonal therapy using the aromatase inhibitor exemestane. Given the neuroprotective functions of estrogen and aromatase, we caution that this timing might not be coincidental. Prompt ophthalmoscopic evaluation is thus recommended for any patient who is prescribed treatment with an aromatase inhibitor and subsequently develops visual symptoms.en_HK
dc.languageengen_HK
dc.publisherCancer Information Group, LP.en_HK
dc.relation.ispartofClinical Breast Canceren_HK
dc.subjectAnastrozoleen_HK
dc.subjectExemestaneen_HK
dc.subjectLetrozoleen_HK
dc.subjectMacular holeen_HK
dc.subjectRetinal detachmenten_HK
dc.titleVisual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitorsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1526-8209&volume=9&issue=3&spage=184&epage=6&date=2009&atitle=Visual+impairment+in+myopic+patients+with+breast+cancer+receiving+adjuvant+therapy+with+aromatase+inhibitors.en_HK
dc.identifier.emailEpstein, RJ: repstein@hku.hken_HK
dc.identifier.authorityEpstein, RJ=rp00501en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.3816/CBC.2009.n.030en_HK
dc.identifier.pmid19661043-
dc.identifier.scopuseid_2-s2.0-70350761930en_HK
dc.identifier.hkuros162576en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-70350761930&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume9en_HK
dc.identifier.issue3en_HK
dc.identifier.spage184en_HK
dc.identifier.epage186en_HK
dc.identifier.isiWOS:000268628600008-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridEpstein, RJ=34975074500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats